SwitzerlandSwitzerland

Clariant to take over German Süd-Chemie AG for EUR2bn

18.02.2011

Muttenz/Munich – Swiss chemistry specialist Clariant AG had made a 2bn bid for Munich-based catalysis and adsorbents specialist Süd-Chemie aimed at taking over the controlling majority from two groups of stockholders. The transaction, which is based on definite agreements with One Equity Partners who hold 50.4% of Süd-Chemie’s shares and the family shareholders (46%), is still subject to clearance by competent merger control authorities. When the deal goes through, Clariant will bag more than 95% of the outstanding shares. Süd-Chemie has a strong R&D pipeline that addresses future needs of the chemistry industry. The company has developed a economically promising approach in advanced development stage to generate cellulosic ethanol from the world’s most common straw feeds – rice straw, corn stover and bagasse. The Sun Liquid process, which has been proven economically feasible at pilot scale, is ready to be tested in a demonstration plant later this year. The company aimed at licensing out the technology world-wide as entry point to plant-based C-2 chemistry building blocks for manufacture of bulk bioplastics such as polyethylene, polypropylene or polyvinyl chloride. As a global leader in process catalysis and adsorbents Süd-Chemie provides the missing link between chemical process engineering and biocatalysis. In 2010, the Munich-based company had a turnover of EUR1.225 billion and EBITDA of EUR 191 million. After the acquisition of Danish Danico by US chemistry giant DuPont, Süd-Chemie has become is the second strategic target involving a world-leading biotechnology product pipeline. The issue of new shares is subject to approval at the Clariant general meeting on March 31, 2011.

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/clariant-to-take-over-german-sued-chemie-ag-for-eur2bn.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • CYTOS1.10 CHF7.84%
  • WILEX3.40 EUR6.25%
  • 4SC1.28 EUR4.07%

FLOP

  • BIOFRONTERA2.36 EUR-6.35%
  • FORMYCON29.79 EUR-6.35%
  • STRATEC BIOMEDICAL47.35 EUR-5.66%

TOP

  • 4SC1.28 EUR52.4%
  • VITA 346.59 EUR18.7%
  • CO.DON3.11 EUR17.8%

FLOP

  • MOLOGEN5.10 EUR-35.4%
  • CYTOS1.10 CHF-28.6%
  • BIOFRONTERA2.36 EUR-10.9%

TOP

  • SANTHERA100.80 CHF2511.4%
  • CYTOS1.10 CHF746.2%
  • FORMYCON29.79 EUR328.6%

FLOP

  • MOLOGEN5.10 EUR-54.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.36 EUR-29.6%

No liability assumed, Date: 24.04.2015

Current issue

All issues